Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis

BMC Infectious Diseases

Shan-Chwen Chang⁴  Yee-Chun Chen⁴  Jann-Tay Wang¹  Hsin-Yun Sun¹  Wang-Huei Sheng¹  Chien-Yu Cheng³  Yu-Chung Chuang² 

[1] Department of Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei 100, Taiwan;Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei Taiwan;Department of Internal Medicine, Tao-Yuan General Hospital, Tao-Yuan, Taiwan;Department of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

关键词: Nephrotoxicity;    Mortality;    Tigecycline;    Colistin;    Pneumonia;    Acinetobacter baumannii;   

Others  :  1134488
DOI  :  10.1186/1471-2334-14-102

 received in 2013-10-28, accepted in 2014-02-10,  发布年份 2014

【 摘 要 】

Background

Colistin and tigecycline have both been shown good in vitro activity among multi-drug resistant Acinetobacter baumannii (MDRAB). A comparative study of colistin versus tigecycline for MDRAB pneumonia is lacking.

Methods

The study enrolled adults with MDRAB pneumonia admitted to intensive care units at a referral medical center during 2009–2010. Since there were no standardized minimum inhibitory concentration (MIC) interpretation criteria of tigecycline against A. baumannii, MIC of tigecycline was not routinely tested at our hospital. During the study periods, MIC of colistin was not routinely tested also. We consider both colistin and tigecycline as definite treatments of MDRAB pneumonia. Patients who received tigecycline were selected as potential controls for those who had received colistin. We performed a propensity score analysis, by considering the criteria of age, gender, underlying diseases, and disease severity, in order to match and equalize potential prognostic factors and severity in the two groups.

Results

A total of 294 adults with MDRAB pneumonia were enrolled, including 119 who received colistin and 175 who received tigecycline. We matched 84 adults who received colistin with an equal number of controls who received tigecycline. The two well matched cohorts share similar characteristics: the propensity scores are colistin: 0.37 vs. tigecycline: 0.37, (P = .97); baseline creatinine (1.70 vs. 1.81, P = .50), and the APACHE II score (21.6 vs. 22.0, P = .99). The tigecycline group has an excess mortality of 16.7% (60.7% vs. 44%, 95% confidence interval 0.9% – 32.4%, P = .04). The excess mortality of tigecycline is significant only among those with MIC >2 μg/mL (10/12 vs. 37/84, P = .01), but not for those with MIC ≦ 2 μg/mL (4/10 vs. 37/84, P = .81).

Conclusions

Our data disfavors the use of tigecycline-based treatment in treating MDRAB pneumonia when tigecycline and colistin susceptibilities are unknown, since choosing tigecycline-based treatment might result in higher mortality. The excess mortality of tigecycline-based group may be related to higher MIC of tigecycline (> 2 μg/mL). Choosing tigecycline empirically for treating MDRAB pneumonia in the critical setting should be cautious.

【 授权许可】

   
2014 Chuang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Perez-Paredes C, Barrero-Almodovar AE, Gili-Miner M: Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001, 33(7):939-946.
• [2]Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21(3):538-582.
• [3]Karageorgopoulos DE, Falagas ME: Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008, 8(12):751-762.
• [4]Fishbain J, Peleg AY: Treatment of Acinetobacter infections. Clin Infect Dis 2010, 51(1):79-84.
• [5]Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D: Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008, 32(1):29-32.
• [6]Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME: Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008, 62(1):45-55.
• [7]Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittel IM, Gallego-Lara SL, Madrazo-Osuna J: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003, 36(9):1111-1118.
• [8]Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC: What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? a systematic review and meta-regression. Clin Infect Dis 2012, 54(5):670-680.
• [9]American Thoracic Society; Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171(4):388-416.
• [10]Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M: Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010, 138(6):1333-1339.
• [11]Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honore PM: Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011, 1(1):14. BioMed Central Full Text
• [12]Schafer JJ, Goff DA, Stevenson KB, Mangino JE: Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007, 27(7):980-987.
• [13]Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E: Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008, 46(4):567-570.
• [14]Jean SS, Hsueh PR: Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin Pharmacother 2011, 12(14):2145-2148.
• [15]Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, Bhargava A, Campbell M, Khandker N, Lephart PR, Chopra T, Hayakawa K, Martin ET, Abreu-Lanfranco O, Dhar S, Kaye KS, Marchaim D, et al.: Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 2012, 40(10):983-987.
• [16]Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18(3):268-281.
• [17]Chuang YC, Chen YC, Chang SC, Sun CC, Chang YY, Chen ML, Hsu LY, Wang JT: Secular trends of healthcare-associated infections at a teaching hospital in Taiwan, 1981–2007. J Hosp Infect 2010, 76:143-149.
• [18]Schreckenberger PC, von Graevenitz A: Acinetobacter, Achromobacter, Acaligenes, Moraxella, Methylobacterium, And Other Nonfermentative Gram-Negative Rods. In Manual Of Clinical Microbiology. 7th edition. Edited by Murray EJB PR, Pfaller MA, Tenover FC, Yolken RH. Washington, D.C: ASM Press; 2000:539-560.
• [19]Clinical and Laboratory Standards Institute: Performance Standards For Antimicrobial Susceptibility Testing: 17th Informational Supplement, M100-S17. Wayne, PA: CLSI; 2007.
• [20]Fernandez-Mazarrasa C, Mazarrasa O, Calvo J, del Arco A, Martinez-Martinez L: High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest. J Clin Microbiol 2009, 47(3):827-829.
• [21]Napolitano LM: Use of severity scoring and stratification factors in clinical trials of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 2010, 51(Suppl 1):S67-S80.
• [22]Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC: Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010, 35(3):297-300.
• [23]Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70(1):41-55.
• [24]Luo Z, Gardiner JC, Bradley CJ: Applying propensity score methods in medical research: pitfalls and prospects. Med Care Res Rev 2010, 67(5):528-554.
• [25]Conte JE Jr, Golden JA, Kelly MG, Zurlinden E: Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005, 25(6):523-529.
• [26]Prasad P, Sun J, Danner RL, Natanson C: Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012, 54(12):1699-1709.
• [27]Cai Y, Wang R, Liang B, Bai N, Liu Y: Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011, 55(3):1162-1172.
• [28]Yahav D, Lador A, Paul M, Leibovici L: Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011, 66(9):1963-1971.
• [29]Food and Drug Administration: FDA drug safety communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm webcite. Accessed 17 February 2014
• [30]Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC: Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013, 57(4):1756-1762.
• [31]Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N: High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? a preliminary study. Clin Infect Dis 2012, 54(12):1720-1726.
• [32]Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A: Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006, 12(12):1227-1230.
• [33]Hope R, Warner M, Mushtaq S, Ward ME, Parsons T, Livermore DM: Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J Antimicrob Chemother 2005, 56(6):1042-1046.
• [34]Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O’Connell J: Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 2005, 49(9):3903-3909.